[ad_1]
BBefore remdesivir became a household name, Gilead Sciences’ most discussed drug was filgotinib, a treatment for inflammatory diseases that is expected to generate billions of dollars in new revenue at a time when biotechnology is desperately needed. All of this was put in jeopardy on Tuesday night.
The FDA has rejected Gilead’s request to sell filgotinib as a treatment for rheumatoid arthritis and said it will not reconsider until the company can provide more data on the drug’s effect on the sperm count of patients. patients. Gilead is conducting two studies to determine exactly that, but it won’t have results until next year.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
TO START
What is that?
STAT Plus is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmacy, policy and life sciences. Our award-winning team covers news from Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, and healthcare disruptions in Silicon Valley and beyond.
What’s included?
- Daily reports and analyzes
- Industry’s most comprehensive coverage by a team of powerful journalists
- Subscriber newsletters
- Daily newsletters to keep you informed about the most important news in the sector
- STAT + conversations
- Weekly opportunities to engage with our journalists and leading industry experts in live video chats
- Exclusive industry events
- Premium access to subscriber-only networking events nationwide
- The best reporters in the industry
- The most reliable and best connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and high-end tools, like our CRISPR Trackr.
[ad_2]
Source link